BV100 (300 mg)

DRUG3 trials

Sponsors

BioVersys AG, BioVersys SAS

Conditions

Acinetobacter Baumannii-calcoaceticus ComplexBacterial InfectionsColistin Resistanrt ABCHealthy Adult ParticipantsHospital Acquired Bacterial Pneumonia (HABP)Ventilator Associated Bacterial Pneumonia (VABP)

Phase 1

To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100

CompletedNCT05684718

BioVersys AGBacterial Infections

Start: 2023-02-01End: 2023-10-31Updated: 2023-11-21

A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers

RecruitingNCT07580586

BioVersys SASHealthy Adult Participants

Start: 2026-03-22End: 2026-12-30Target: 16Updated: 2026-05-12

Phase 3

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

RecruitingNCT07326540

BioVersys SASAcinetobacter Baumannii-calcoaceticus Complex, Colistin Resistanrt ABC, Hospital Acquired Bacterial Pneumonia (HABP) +1

Start: 2026-03-27End: 2028-03-30Target: 248Updated: 2026-05-04